Immune Dysfunction in Chronic Lymphocytic Leukemia T Cells and Lenalidomide as an Immunomodulatory Drug

Haematologica - Italy
doi 10.3324/haematol.2009.009274
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

Regulatory T-Cells in Chronic Lymphocytic Leukemia

Mediterranean Journal of Hematology and Infectious Diseases
Infectious DiseasesHematology
2012English

Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia

Cold Spring Harbor perspectives in medicine
BiochemistryMedicineGeneticsMolecular Biology
2017English

T Cells in Chronic Lymphocytic Leukemia Display Dysregulated Expression of Immune Checkpoints and Activation Markers

Haematologica
Hematology
2016English

Treatment With Lenalidomide Modulates T-Cell Immunophenotype and Cytokine Production in Patients With Chronic Lymphocytic Leukemia

Cancer
Cancer ResearchOncology
2011English

Management of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide

Clinical Journal of Oncology Nursing
Oncology
2010English

Drug-Induced Apoptosis in Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
1999English

HLA Ligandome Analysis of Primary Chronic Lymphocytic Leukemia (CLL) Cells Under Lenalidomide Treatment Confirms the Suitability of Lenalidomide for Combination With T-Cell-Based Immunotherapy

OncoImmunology
OncologyAllergyImmunology
2018English

The Impacts of Zanubrutinib on Immune Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Immune Failure, Infection and Survival in Chronic Lymphocytic Leukemia in Denmark

Haematologica
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy